Please enable JavaScript, then refresh this page. JavaScript is required on this site. features remarks by Todd Harrison about what’s in store for CBD

On January 3, 2019, featured remarks by Todd Harrison about the 2018 Agricultural Improvement Act's ("Farm Bill") implications for CBD and understanding what you're marketing and your risk tolerance. Here is an excerpt:

While the Farm Bill has removed industrial hemp from Schedule I of the Controlled Substances Act, the use of CBD as an ingredient has many more hurdles to overcome especially with the FDA, according to Mr. Harrison.

Harrison said that marketing a hemp extract containing 5% or 10% CBD as opposed to a CBD isolate are two very different situations and arguments.

"You're never going to convince the FDA that the pure CBD isolate ingredient is appropriate, but we can start stepping things down," Harrison said.

Companies that have received FDA warning letters have primarily those marketing products with pure CBD extracts, Harrison explained.

The companies that have a stronger shot in the marketplace are ones marketing non-standardized hemp extracts, according to Harrison.